OptimizeRx (OptimizeRx) Valuation Rank

View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

OptimizeRx Valuation Rank Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

OptimizeRx (OptimizeRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Water Street, Suite 200, Rochester, MI, USA, 48307

Website

https://www.optimizerx.com

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Executives

Marion Odence-ford	officer: General Counsel and CCO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco	officer: Chief Commercial Officer	260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch	officer: Chief Product Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo	officer: Chief Executive Officer	600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro	officer: Chief Commercial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh	officer: COO and CFO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore	officer: President	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler	director, officer: SVP of Product & Strategy	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker	officer: Chief Financial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman	officer: Chief Technology Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson	director	200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas	director	38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022